United Medical Systems Partners With IceCure For Treatment Of Fibroadenoma

United Medical Systems (UMS) announces it has entered into an exclusive agreement in the United States with IceCure Medical (IceCure), an innovative provider of medical technology from Israel. The agreement provides for the mobile deployment of IceCure's medical product IceSense3 for cryoablation.


IceSense3 is approved by the Food and Drug Administration for the treatment of benign tumors in the breast (fibroadenoma). In the United States alone, approximately 500,000 of these tumors are surgically removed every year. The partnership with IceCure adds a new treatment to UMS's breast care segment. UMS plans to build up the US market for mobile services using IceSense3 in the next six to twelve months by offering onsite mobile cryoablation systems in combination with modern ultrasound technology.


UMS is an international leader in shared medical services providing mobile services to over 650 hospitals and medical centers in 32 states in addition to sites in Canada and South America. Other mobile services include extracorporeal shockwave lithotripsy, stereotactic breast biopsy and laser treatment of BPH.


Source:

United Medical Systems